BioSpace News Archive

Drug Development

Novartis’ Ilaris Fails to Meet Endpoints in COVID-19 Study

This morning, the Swiss pharma giant announced Ilaris plus standard of care did not demonstrate a significantly greater chance of survival for patients without the need for invasive mechanical ventilation, compared with placebo plus the standard of care.

November 6, 2020
·
2 min read
·
Alex Keown
Drug Development

Inexpensive Nasal Spray Prevents COVID-19 Infection in Ferrets, Shows Promise for Human Trials

A multi-institutional research team has developed a nasal spray that effectively blocks absorption of the SARS-CoV-2 virus in ferrets with direct contact to infected animals.

November 6, 2020
·
3 min read
·
Brandon May
Deals

Pandemic Provides Silver Linings and FDA Delays for BMS

Setbacks and delays caused by COVID-19 are making everyone, in every facet of life, nervous. This week, that includes legacy Celgene CVR investors who are staging a mass exodus as two drugs under the agreement near the deadline and one, Liso-cel, faces inspection delays.

November 6, 2020
·
2 min read
·
Heather McKenzie
BioForest

Clinical Catch-Up: November 2-6

It was relatively quiet in terms of COVID-19-related clinical trials, but there was still quite a bit of news for trials involving other indications. Here’s a look.

November 6, 2020
·
9 min read
·
Mark Terry
Drug Development

Positive Clinical Trial News: Janssen, Humanigen, Pfizer, Equillium and ChemoCentryx

There was a handful of positive clinical trial news reported today. Here’s a look.

November 6, 2020
·
3 min read
·
Mark Terry
Drug Development

Assembly Biosciences Falls Short with Hepatitis B Drug in Phase 2 Study

Assembly Biosciences, Inc. provided an update on Nov. 5 of its ongoing Phase 2 extension study, Study 211, examining vebicorvir (VBR, or ABI-H0731) in patients with hepatitis B virus infection.

November 6, 2020
·
3 min read
·
Krystle Vermes
FDA

FDA Action Alert: Supernus, Adamis, Alkermes, Amgen, BMS and Eiger

Here’s a look at some of the upcoming target action dates on the U.S. FDA’s calendar.

November 6, 2020
·
4 min read
·
Mark Terry
FDA

AstraZeneca’s Brilinta Approved to Reduce Risk of Recurring Stroke in Patients

The latest approval for Brilinta is based on the Phase III THALES trial that showed aspirin plus 90 mg of Brilinta significantly reduced the rate of the composite of stroke and death compared to aspirin alone in patients with acute ischemic stroke or TIA.

November 6, 2020
·
3 min read
·
Alex Keown
Drug Development

Sanofi Hits the Brakes on Its Hemophilia Program

Three hemophilia organizations issued a joint statement reporting that Sanofi Genzyme had placed a global dosing hold on its full clinical development program.

November 6, 2020
·
2 min read
·
Mark Terry
Business

Novo Nordisk Acquires Emisphere Tech in $1.8 Billion Deal

Denmark’s Novo Nordisk is acquiring New Jersey-based Emisphere Technologies in a deal worth about $1.8 billion. Novo Nordisk and Emisphere have been partnered since 2007.

November 6, 2020
·
2 min read
·
Mark Terry